What changes and trends could we see this year? WashU experts in areas from artificial intelligence to climate to fashion share their insights.
While there are signs the economic conditions are improving, small businesses are more likely to feel the pinch of rising interest rates, a looming recession threat and persistent labor shortages in 2023, according to Olin Business School’s Peter Boumgarden.
Radhakrishnan Gopalan, a longtime, beloved professor of finance at Olin Business School, died Dec. 6, 2022, of cancer. He was 50.
With so much uncertainty, how can businesses gain a competitive edge going into the new year and beyond — better anticipating threats created by competitors, the economy, suppliers, politicians and more? One way is through the process of “war gaming,” says John Horn, a competitive strategy expert at Olin Business School.
After a distinguished career in international banking and hospitality investing, Albert Ip, BSAMCS ’73, advocates for WashU in Hong Kong.
As founder and CEO of City Winery, a national chain of music venues that offers wine and fine dining, Michael Dorf, AB ’84, BSBA ’84, has made it his mission to provide an experience that will “indulge the senses.”
If changes at Twitter conflict with businesses’ values, it’s time for companies to re-evaluate use of the social media platform, said Olin Business School marketing expert Michael Wall.
Philip H. Dybvig, a banking and finance expert at Washington University in St. Louis, is one of three economists to share the 2022 Nobel Prize in economic sciences, the Royal Swedish Academy of Sciences announced Monday, Oct. 10.
New Olin Business School research suggests those touched by the sometimes devastating effects of the COVID-19 pandemic are now more likely to recognize sources of inequality and, in turn, advocate for greater equality in the United States.
The White House has sounded the alarm about vulnerabilities in the pharmaceutical supply chain. But new research from the Center for Analytics and Business Insights at Olin Business School found that the U.S. actually has the capacity to make the nation’s most essential and critical drugs — yet it’s mostly sitting idle.